Clinical Trial Update: Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 [Phase 1]

View source ↗

Summary

The Phase 1 trial of AB-201 for breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• AB-201

Snippet

Sponsor: GC Cell Corporation | Conditions: Breast Cancer, Gastric Cancer | Phase 1 | Status: WITHDRAWN